摘要
肝细胞癌(HCC)伴门静脉癌栓(PVTT)患者病情发展迅速,预后差,严重危及患者生命。目前HCC伴PVTT可选择的治疗方式主要有经肝动脉介入治疗、放射治疗(简称放疗)、靶向治疗、免疫治疗、手术等,但尚无标准治疗方案。调强放疗可显著提高肿瘤剂量,同时可以更好地保护剩余肝,保证了肝癌放疗的安全性,临床研究的结果也证实了HCC伴PVTT放疗是安全有效的。随着多学科治疗理念的深入,放疗联合多种治疗手段逐渐应用于HCC伴PVTT患者的治疗中。本文主要以HCC伴PVTT的放疗为中心,探讨放疗与手术、介入治疗、靶向治疗、免疫治疗等多学科联合治疗的进展。
With a poor prognosis,hepatocellular carcinoma(HCC)with portal vein tumor thrombus(PVTT)progresses rapidly and is life-threatening.Currently,the treatment options for HCC with PVTT mainly include transcatheter arterial intervention,radiotherapy,targeted therapy,immunotherapy,surgery,etc.,but there is still no standard treatment strategy.Intensity-modulated radiotherapy can significantly raise the prescribed dose with the minimum dose delivery to the remaining liver,ensuring the safety of radiotherapy for HCC.Previous clinical studies have confirmed the safety and efficacy of radiotherapy for HCC with PVTT.With the deepening of the multidisciplinary treatment concept,radiotherapy combined with other treatments for HCC with PVTT has been continuously explored.Focusing on radiotherapy for HCC with PVTT,this review mainly discusses the progress of multidisciplinary combined therapy including radiotherapy,surgery,interventional therapy,targeted therapy,and immunotherapy.
作者
辛玲霞
许新
翟医蕊
邓敏
陈波
Xin Lingxia;Xu Xin;Zhai Yirui;Deng Min;Chen Bo(Department of Radiation Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)
出处
《肝癌电子杂志》
2023年第3期76-82,共7页
Electronic Journal of Liver Tumor
基金
中国癌症基金会北京希望马拉松专项基金资助(LC2020A03)
中国医学科学院医学与健康科技创新工程经费资助(2021-I2M-1-066)。
关键词
肝细胞癌
门静脉癌栓
放射治疗
Hepatocellular carcinoma
Portal vein tumor thrombus
Radiotherapy
